Scientific Study Reveals E-cigarettes Can Alter Human DNA

Industry Insight by 2FIRSTS.ai
Apr.08.2024
Scientific Study Reveals E-cigarettes Can Alter Human DNA
Scientists from the University of California and the University of Innsbruck have found e-cigarettes can alter human DNA, research shows.

According to a report from Secretmag, scientists have discovered that e-cigarettes can alter human DNA. Scientists from the University of California (USA) and the University of Innsbruck (Austria) have found that changes in cheek cells are similar to those observed in regular cigarette smokers. They analyzed the epigenome, which is the information layer of DNA. Over 3,500 people participated in this new study.

 

According to Professor Martin Vidshvendtera, studying the phenotype genome of cells allows us to understand how the body responds to environmental factors such as smoking. He said, "In the same way, studying the phenotype genome can also help us predict future health conditions and diseases.

 

According to the latest scientific research, scientists have concluded through experiments that the population of people who use traditional tobacco and e-cigarettes have almost identical changes in their phenotypic genome. This phenomenon has even been observed in individuals who smoke less than 100 cigarettes. The changes in the phenotypic genome result in cancer cells growing faster within the epithelium.

 

Researchers believe that this new study confirms a theory that e-cigarettes are not as safe as the general public believes. Scientists at the University of Pittsburgh in the United States previously found that mint-flavored e-liquid is the least healthy option. This is because it produces the highest amount of toxic particles when mixed with other substances.

 

The consequences on the body include worsening lung function. Research has found that individuals who inhale menthol have less lung capacity compared to those who inhale other substances, regardless of age.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape has launched Labster, a 700 sq m production unit in the Lyon Metropolis near the group’s headquarters, for e-liquids and DIY concentrates. The site is equipped with automated lines supplied by CDA (Constructions d’Automatismes) to carry out bottling and labeling. Its theoretical capacity is described as several million bottles per year in 10–100 ml formats, and it is already operational.
Feb.06 by 2FIRSTS.ai
Arizona Moves to Tighten Vape Supply-Chain Enforcement, Targeting Illicit Products
Arizona Moves to Tighten Vape Supply-Chain Enforcement, Targeting Illicit Products
Arizona state Sen. Shawnna Bolick introduced SB 1397 to curb illicit vapes by tracing product origins, intercepting illegal shipments, and cracking down on retailers that violate state law. The proposal would require manufacturers to hold a state license to sell in Arizona, with fines up to $10,000 for unlicensed sales.
Jan.30 by 2FIRSTS.ai
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s National Agency for Food, Environmental and Occupational Health & Safety (ANSES) says vaping poses health risks because users inhale toxic or harmful substances, even if e-cigarettes are generally considered less harmful than cigarettes.
Feb.04 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
UK vape firm Plxsur sold for £76,500 after touting $1 billion revenue target
UK vape firm Plxsur sold for £76,500 after touting $1 billion revenue target
London-based vaping company Plxsur, which had claimed in fundraising materials it could reach $1 billion in annual revenue and capture about 10% of the global vaping market, has been sold out of administration for £76,500. Administrators said the figures were aspirational and depended on acquisitions that were never completed, as the company later ran out of cash and entered insolvency, with a shareholder ultimately buying the business.
Jan.22 by 2FIRSTS.ai